

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

ETAS ID: TM502950

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
ROS Acquisition Offshore LP		12/20/2018	Limited Partnership:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Rapid Pathogen Screening, Inc.		
<b>Street Address:</b>	7227 Delainey Court		
<b>City:</b>	Sarasota		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	34240		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4002986	RIGHT DIAGNOSIS RIGHT TREATMENT RIGHT NO	
<b>Registration Number:</b>	3371185	RPS	
<b>Registration Number:</b>	4305076	ADENOPLUS	
<b>Registration Number:</b>	4400234	INFLAMMADRY	
<b>Serial Number:</b>	85566525	ORGANOTOX	
<b>Serial Number:</b>	85839245	FEBRIDX	
<b>Serial Number:</b>	86098847	ADENOGEN	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	4159472099		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	4159472000		
<b>Email:</b>	qluflood@wsgr.com		
<b>Correspondent Name:</b>	WSGR, C/O QUI LU FLOOD, SENIOR PARALEGAL		
<b>Address Line 1:</b>	ONE MARKET, SPEAR TOWER, SUITE 3300		
<b>Address Line 4:</b>	SAN FRANCISCO, CALIFORNIA 94105		
<b>ATTORNEY DOCKET NUMBER:</b>	54675.006		
<b>NAME OF SUBMITTER:</b>	Qui Lu Flood		
<b>SIGNATURE:</b>	/Qui Lu Flood/		

CH \$190.00 4002986

DATE SIGNED:	12/20/2018
<b>Total Attachments: 12</b> source=RPS - Release of Security Interest in IP (Executed Version)#page1.tif source=RPS - Release of Security Interest in IP (Executed Version)#page2.tif source=RPS - Release of Security Interest in IP (Executed Version)#page3.tif source=RPS - Release of Security Interest in IP (Executed Version)#page4.tif source=RPS - Release of Security Interest in IP (Executed Version)#page5.tif source=RPS - Release of Security Interest in IP (Executed Version)#page6.tif source=RPS - Release of Security Interest in IP (Executed Version)#page7.tif source=RPS - Release of Security Interest in IP (Executed Version)#page8.tif source=RPS - Release of Security Interest in IP (Executed Version)#page9.tif source=RPS - Release of Security Interest in IP (Executed Version)#page10.tif source=RPS - Release of Security Interest in IP (Executed Version)#page11.tif source=RPS - Release of Security Interest in IP (Executed Version)#page12.tif	

**RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This Release of Security Interest in Intellectual Property, dated as of December 20, 2018 (this “**IP Collateral Release**”), is made by **ROS ACQUISITION OFFSHORE LP** (the “**Lender**”) in favor of **RAPID PATHOGEN SCREENING, INC.** (the “**Grantor**”).

WHEREAS, pursuant to that certain Patent Security Agreement, dated as of October 10, 2014 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**Patent Security Agreement**”), recorded with the United States Patent and Trademark Office on October 10, 2014 at Reel/Frame No. 033929/0786, the Grantor granted Lender a security interest in and to all of its right, title and interest in all of the Grantor’s Patent Collateral (as defined therein), including those listed on Schedule I thereto;

WHEREAS, pursuant to that certain Trademark Security Agreement, dated as of October 10, 2014 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**Trademark Security Agreement**”), recorded with the United States Patent and Trademark Office on October 10, 2014 at Reel/Frame No. 5379/0116, the Grantor granted Lender a security interest in and to all of its right, title and interest in all of the Grantor’s Trademark Collateral (as defined therein), including those listed on Schedule I thereto;

WHEREAS, the Grantor has requested that Lender release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantor has requested that Lender release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantor has requested that Lender release its security interest in and to the Patent Collateral (as defined in the Patent Security Agreement) and the Trademark Collateral (as defined in the Trademark Security Agreement) (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, the Lender, without recourse, representation or warranty and at Grantor’s sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Lender has caused this IP Collateral Release to be duly executed and delivered as of the date first written above.

Very truly yours,

ROS ACQUISITION OFFSHORE LP,  
as the Lender

By OrbiMed Advisors LLC, solely in its  
capacity as Investment Manager

By:

Name:

Title:

W. Carter Neild  
W. Carter Neild  
Member

**SCHEDULE A**

**[See attached]**

Item A. Patents

Issued Patents

<u>Country</u>	<u>Patent #</u>	<u>Issue Date</u>	<u>Title</u>
US	7,723,124	5/25/10	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
US	8,647,890	2/11/14	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
EP	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
AU	2005210742	9/22/11	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
CA	2554904	1/22/13	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
UK	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
FR	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
DE	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
IT	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
ES	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
CH	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
AT	1718973	9/9/09	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
US	8,445,293	5/21/13	Method To Increase Specificity And/Or Accuracy Of Lateral Flow Immunoassays

US	8,614,101	12/24/13	In Situ Lysis Of Cells In Lateral Flow Immunoassays
US	8,470,608	6/25/13	Combined Visual/Fluorescence Analyte Detection Test
US	8,609,433	12/17/13	Multiplanar Lateral Flow Immunoassay With Sample Compressor
US	8,815,609	8/26/14	Multiplanar Lateral Flow Assay With Diverting Zone

### Pending Patent Applications

<u>Country</u>	<u>Serial #</u>	<u>Filing date</u>	<u>Title</u>
US	14/084,973	11/20/13	Method for the Rapid Diagnosis of Targets in Human Body Fluids
US	13/800,114	3/13/13	Method to Increase Specificity and/or Accuracy of Lateral Flow Immunoassays
US	13/463,126	5/3/12	Methods And Devices For Using Mucolytic Agents Including N-Acetyl Cysteine (NAC)
US	12/782,162	5/18/10	Combined Detection Test for Viral and Bacterial Infections
US	13/762,495	2/8/13	Combined Detection Test for Viral and Bacterial Infections
US	13/790,125	3/8/13	Combined Detection Test for Viral and Bacterial Infections
US	13/790,160	3/8/13	Combined Detection Test for Viral and Bacterial Infections
US	13/796,736	3/12/13	Multiplanar lateral flow immunoassay with sample compressor
US	14/215,602	3/17/14	Multiplanar lateral flow immunoassay with sample compressor
US	13/553,011	7/19/12	Enzymatic Cleavage Based Lateral Flow Assay
US	13/622,791	9/19/12	Lateral Flow Assays with Time Delayed Components

US	13/788716	3/7/13	Optimization of Expression and Purification of Recombinant Human MxA Protein in E.coli
US	13/788,761	3/7/13	Histatin For Corneal Wound Healing And Ocular Surface Disease
US	13/796,560	3/12/13	Detection of Exposure to Chemical Warfare Nerve Agents with Lateral Flow Assays
US	14/198,908	3/6/14	Lateral Flow Assays
US	13/788,803	3/7/13	Histatin For Corneal Wound Healing And Ocular Surface Disease
JP	2006551826	2/9/05	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
JP	2012142452	6/25/12	Method For The Rapid Diagnosis Of Targets In Human Body Fluids
JP	2011-528055	3/18/11	Combined Detection Test For Viral And Bacterial Infections
EP	09815363.8	4/6/11	Combined Detection Test For Viral And Bacterial Infections
PCT	PCT/US14/19771	3/3/14	Combined Detection Test For Viral And Bacterial Infections
AU	2010325893	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
BR	PI BR 112012 012342 4	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
CA	2780751	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
EP	10835165.1	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
JP	2012-542210	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
KR	10-2012-7017244	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor
RU	2012125201	12/3/10	Multiplanar Lateral Flow Immunoassay With Sample Compressor



EP	12818249	11/19/13	Enzymatic Cleavage Based Lateral Flow Assays
PCT	PCT/US14/19773	3/3/14	Multiplanar Lateral Flow Assay With Diverting Zone
PCT	PCT/US13/44244	6/5/13	Optimization Of Expression And Purification Of Recombinant Human Mxa Protein In E.Coli
PCT	PCT/US13/40506	5/10/13	Histatin For Corneal Wound Healing And Ocular Surface Disease
PCT	PCT/US14/19778	3/3/14	Detection Of Exposure To Chemical Warfare Nerve Agents With Lateral Flow Assays

### Patent Applications in Preparation

<u>Country</u>	<u>Docket #</u>	<u>Expected Filing Date</u>	<u>Title</u>
US	RP2-36DIV	Dec-14	Enzymatic Cleavage Based Lateral Flow Assays
US	RP2-47CIP	Dec-14	Formulations for Histatin therapeutics
US	RP2-47CIP2	Dec-14	Formulations for Histatin therapeutics (skin)
US	RP2-47CIP3	Dec-14	Methods of using Histatins to prevent and treat Bovine Mastitis

### Item B. Patent Licenses

<u>Country</u>	<u>Licensor</u>	<u>Licensee</u>	<u>Effective Date</u>	<u>Expiration Date</u>	<u>Subject Matter</u>
Worldwide	Kyowa	RPS	12/22/2008 (amended 1/1/2012, 1/1/2013 & 7/1/2013)	10 years after 1 <sup>st</sup> commercial sale of lateral flow device (has not occurred)	Lateral Flow Test Using Antibodies to MxA (used in FebriDx)
Worldwide	Kyowa	RPS	7/1/2013	10 years after 1 <sup>st</sup> commercial sale of lateral flow device (has not occurred)	MxA ELISA Test for Animal (non-human) Diagnosits

Worldwide	Kyowa	RPS	7/1/2013	10 years after 1 <sup>st</sup> commercial sale of lateral flow device (has not occurred)	Lateral Flow Test Using Antibodies to MxA (used in FebriDx) for Animal (non-human) Diagnosits
Worldwide	Securetec	RPS	9/29/2008	Life of Patents (Paid up License)	Infectious disease, inflammation markers, genetic testing, drugs of abuse tests (includes license to U.S. Patent No. 6,514,773, <i>Method of Detecting Surface Contamination by an Analyte</i> )
Worldwide	ACTA	RPS	11/30/2010	10 years after 1 <sup>st</sup> commercial sale (has not occurred)	The use of histatin as a therapeutic
Worldwide	HEK	RPS	10/30/2013	10/31/2014	Marketing of patents for treatment of presbyopia

**SCHEDULE B**

**[See attached]**

Item A. Trademarks

Registered Trademarks

<u>Country</u>	<u>Mark</u>	<u>Reg. No./Ser. No.</u>	<u>Reg. date</u>
US	Right Diagnosis Right Treatment Right Now	4,002,986	7/26/11
EC	Febridx	11690981	8/23/13
US	RPS	3,371,185	1/22/08
US	AdenoPlus	4,305,076	3/19/13
US	Inflammdry	4,400,234	9/10/13
CA	Inflammdry	1614901	8/19/14
EC	Inflammdry	011639739	7/31/13
EC	Febridx	11690981	8/23/13
Australia	RPS (Australia)	1157793	6/13/07
Canada	RPS (Canada)	TMA816031	1/24/12
European Community	RPS (European Community)	5666854	1/31/08
Israel	RPS (Israel)	197264	8/6/08
Japan	RPS (Japan)	5053758	6/8/07
Kuwait	RPS (Kuwait)	71255	6/1/08
Switzerland	AdenoPlus	649477	10/9/13

European Community	AdenoPlus	11073161	12/20/12
Hong Kong	AdenoPlus	302613221	5/21/13
Japan	AdenoPlus	5554488	2/1/13
Korea	AdenoPlus	40-1028835	3/21/14
Mexico	AdenoPlus	1405964	10/23/13
Norway	AdenoPlus	272080	9/4/13
Turkey	AdenoPlus	2013/49434	4/10/14

Pending Trademark Applications

<u>Country</u>	<u>Mark</u>	<u>Reg. No./Ser. No.</u>	<u>Filing Date</u>
US	Organotox	85/566,525	3/12/12
US	Febridx	85/839,245	2/2/13
US	Adenogen	86/098,847	10/23/13
Brazil	RPS	92958858	2/5/07
Canada	AdenoPlus	1587946	7/27/12
Brazil	AdenoPlus	84053648	6/5/13
Brazil	AdenoPlus	840536496	6/5/13
China	AdenoPlus	12667685	5/29/13
Russia	AdenoPlus	2013718353	5/24/13

Saudi Arabia	AdenoPlus	200465	8/22/13
South Africa	AdenoPlus	2013/13774	5/24/13

Trademark Applications in Preparation

<u>Country</u>	<u>Trademark</u>	<u>Docket No.</u>	<u>Expected Filing Date</u>	<u>Products/ Services</u>
None				

Item B. Trademark Licenses

<u>Country or Territory</u>	<u>Trademark</u>	<u>Licensor</u>	<u>Licensee</u>	<u>Effective Date</u>	<u>Expiration Date</u>
None					